RT @ericdeinmd: #EULAR2022 LB0001 Bimekizumab (IL-17F and IL-17A) in bionaive PsA BE OPTIMAL phase 3 trial, 24 weeks â
Tweet Content
#EULAR2022 LB0001
Bimekizumab (IL-17F and IL-17A) in bionaive PsA
BE OPTIMAL phase 3 trial, 24 weeks
⭐️Met Primary endpt - ACR50
⭐️Met other ACR and PASI endpts
⭐️Safety: higher fungal infections
@RheumNow https://t.co/x8u6B93FNl
Show on Archive Page
On
Display in Search Results
On
PDQ
Off